{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:10:45Z","timestamp":1789398645926,"version":"build-2803163510"},"reference-count":145,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The occurrence of second primary malignancies is becoming increasingly important among cancer survivors. Melanoma, an aggressive neoplasm originating from the melanocytes, is responsible for most skin cancer-related deaths. This review aims to explore the risk of melanoma occurrence as a second primary cancer after the most common subtypes of hematologic neoplasia, a malignant disease originating from myeloid or lymphocytic cell lineages. Chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) are among the most associated subtypes with melanoma development. We also discuss the underlying hypotheses that may explain the associations between these malignancies and the impact of melanoma on survival. The review emphasizes the importance of increasing awareness of melanoma risk in hematologic cancer survivors, as it can lead to prompt recognition, improved skin surveillance, and better survival outcomes.<\/jats:p>","DOI":"10.3390\/jcm13154501","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T11:34:20Z","timestamp":1722512060000},"page":"4501","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Melanoma as Subsequent Primary Malignancy in Hematologic Cancer Survivors\u2014A Literature Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4990-6217","authenticated-orcid":false,"given":"Salomea-Ruth","family":"Halm\u00e1gyi","sequence":"first","affiliation":[{"name":"Clinical Hospital of Infectious Diseases, 400000 Cluj-Napoca, Romania"},{"name":"Department of Dermatology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8535-9677","authenticated-orcid":false,"given":"Loredana","family":"Ungureanu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"},{"name":"Department of Dermatology, Emergency County Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana-Irina","family":"Trufin","sequence":"additional","affiliation":[{"name":"Clinical Hospital of Infectious Diseases, 400000 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina Patricia","family":"Apostu","sequence":"additional","affiliation":[{"name":"Clinical Hospital of Infectious Diseases, 400000 Cluj-Napoca, Romania"},{"name":"Department of Dermatology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Corina","family":"\u0218enil\u0103","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u201cIuliu Ha\u021bieganu\u201d University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania"},{"name":"Department of Dermatology, Emergency County Hospital, 400006 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"ref_3","unstructured":"SEER [Internet] (2024, April 15). Cancer of Any Site\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/all.html."},{"key":"ref_4","unstructured":"American Cancer Society (2022). Cancer Treatment & Survivorship Facts & Figures 2022\u20132024, American Cancer Society."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.21037\/atm-20-2059","article-title":"Second primary malignancies among cancer patients","volume":"8","author":"Zheng","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1002\/cncr.30164","article-title":"Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008","volume":"122","author":"Donin","year":"2016","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lopes, J., Rodrigues, C.M.P., Gaspar, M.M., and Reis, C.P. (2022). Melanoma Management: From Epidemiology to Treatment and Latest Advances. Cancers, 14.","DOI":"10.3390\/cancers14194652"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"key":"ref_9","unstructured":"SEER [Internet] (2024, April 16). Melanoma of the Skin\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/melan.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e2021161S","DOI":"10.5826\/dpc.11S1a161S","article-title":"Epidemiology and Risk Factors of Melanoma: A Review","volume":"11","author":"Conforti","year":"2021","journal-title":"Dermatol. Pract. Concept"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Feller, A., the NICER Working Group, Matthes, K.L., Bordoni, A., Bouchardy, C., Bulliard, J.-L., Herrmann, C., Konzelmann, I., Maspoli, M., and Mousavi, M. (2020). The relative risk of second primary cancers in Switzerland: A population-based retrospective cohort study. BMC Cancer, 20.","DOI":"10.1186\/s12885-019-6452-0"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/jdv.13645","article-title":"Risk of second primary malignancies among 1537 melanoma patients and risk of second primary melanoma among 52 354 cancer patients in Northern Italy","volume":"30","author":"Caini","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/CMR.0b013e32835f28d8","article-title":"Trends in the risks of melanoma as a second primary cancer among cancer patients in the Netherlands, 1989\u20132008","volume":"23","author":"Liu","year":"2013","journal-title":"Melanoma Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S69.e1","DOI":"10.1016\/j.jaad.2011.04.033","article-title":"Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin","volume":"65","author":"Balamurugan","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Allegra, A., Tonacci, A., Musolino, C., Pioggia, G., and Gangemi, S. (2021). Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.738915"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1055-9965.EPI-06-0414","article-title":"The Epidemiology of Second Primary Cancers","volume":"15","author":"Travis","year":"2006","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100511","DOI":"10.1016\/j.currproblcancer.2019.100511","article-title":"The risk of melanoma in patients with chronic lymphocytic leukemia; A population-based study","volume":"44","author":"Turk","year":"2019","journal-title":"Curr. Probl. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/jnci\/djy052","article-title":"Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival","volume":"110","author":"Herr","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaad.2014.09.030","article-title":"Melanoma in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma","volume":"72","author":"Famenini","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1111\/ijd.12564","article-title":"Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia","volume":"54","author":"Brewer","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/1097-0142(20010215)91:4<874::AID-CNCR1076>3.0.CO;2-O","article-title":"Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma","volume":"91","author":"Goggins","year":"2001","journal-title":"Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ou, Y., Long, Y., Ji, L., Zhan, Y., Qiao, T., Wang, X., Chen, H., and Cheng, Y. (2022). Trends in Disease Burden of Chronic Lymphocytic Leukemia at the Global, Regional, and National Levels From 1990 to 2019, and Projections Until 2030: A Population-Based Epidemiologic Study. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.840616"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Yao, Y., Lin, X., Li, F., Jin, J., and Wang, H. (2022). The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: Analysis based on the global burden of disease study 2019. Biomed. Eng. OnLine, 21.","DOI":"10.1186\/s12938-021-00973-6"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/PPO.0b013e31826cda2d","article-title":"Small lymphocytic lymphoma and chronic lymphocytic leukemia: Are they the same disease?","volume":"18","author":"Santos","year":"2012","journal-title":"Cancer J. Sudbury Mass."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood.V98.6.1979","article-title":"Solid tumors after chronic lymphocytic leukemia","volume":"98","author":"Hisada","year":"2001","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/bjc.2011.313","article-title":"Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: A population-based study","volume":"105","author":"Royle","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second Malignancy Risks After Non-Hodgkin\u2019s Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma Subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ijc.22672","article-title":"Risk of second cancer after chronic lymphocytic leukemia","volume":"121","author":"Rosendahl","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/sj.bjc.6600692","article-title":"Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: A population-based retrospective cohort study in Scotland","volume":"88","author":"McKenna","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_31","first-page":"1","article-title":"Risk of second primary malignancies in patients with chronic lymphocytic leukemia: A population-based study in the Netherlands, 1989\u20132019","volume":"13","author":"Levin","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2008.17.5398","article-title":"Other malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"27","author":"Tsimberidou","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.31557\/APJCP.2023.24.6.1971","article-title":"Evaluation of Second Primary Cancer Risk Among Chronic Lymphocytic Leukemia Patients: Multicenter Study","volume":"24","author":"Sayin","year":"2023","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/bjh.15777","article-title":"Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia","volume":"185","author":"Zheng","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/annonc\/mdw072","article-title":"Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia","volume":"27","author":"Falchi","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jha2.366","article-title":"Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter\u2019s syndrome","volume":"3","author":"Shen","year":"2021","journal-title":"EJHaem"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/pcmr.12926","article-title":"The tumour immune landscape and its implications in cutaneous melanoma","volume":"34","author":"Attrill","year":"2021","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2012.04.018","article-title":"Melanoma in Immunosuppressed Patients","volume":"87","author":"Kubica","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jncimonographs\/lgu001","article-title":"Medical History, Lifestyle, Family History, and Occupational Risk Factors for Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: The InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"48","author":"Slager","year":"2014","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1182\/blood-2011-02-336065","article-title":"Adulthood residential ultraviolet radiation, sun sensitivity, dietary vitamin D, and risk of lymphoid malignancies in the California Teachers Study","volume":"118","author":"Chang","year":"2011","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"62358","DOI":"10.18632\/oncotarget.18140","article-title":"Occupational ultraviolet exposure and risk of non-Hodgkin\u2019s lymphomas: A meta-analysis","volume":"8","author":"Lu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.leukres.2010.03.011","article-title":"The role of Bcl-2 family proteins in chronic lymphocytic leukaemia","volume":"34","author":"Buggins","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.drudis.2021.01.027","article-title":"New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy","volume":"26","author":"Trisciuoglio","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/ajh.24808","article-title":"IGHV Mutational Status Testing in Chronic Lymphocytic Leukemia","volume":"92","author":"Crombie","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102307","DOI":"10.1016\/j.eclinm.2023.102307","article-title":"Other malignancies in the history of CLL: An international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY","volume":"65","author":"Chatzikonstantinou","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1182\/blood.V128.22.4359.4359","article-title":"Incidence and Implications of Skin Cancers in Cancercare Manitoba Chronic Lymphocytic Leukemia (CLL) Clinic Patients","volume":"128","author":"Beiggi","year":"2016","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2016-01-695692","article-title":"Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia","volume":"128","author":"Speedy","year":"2016","journal-title":"Blood"},{"key":"ref_48","first-page":"210","article-title":"Update in genetic susceptibility in melanoma","volume":"3","author":"Potrony","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_49","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J., Gripp, K.V., and Amemiya, A. (2024, February 21). POT1 Tumor Predisposition, GeneReviews\u00ae [Internet], Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563529\/."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Wu, Y., Poulos, R.C., and Reddel, R.R. (2020). Role of POT1 in Human Cancer. Cancers, 12.","DOI":"10.3390\/cancers12102739"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Castellani, G., Buccarelli, M., Arasi, M.B., Rossi, S., Pisanu, M.E., Bellenghi, M., Lintas, C., and Tabolacci, C. (2023). BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. Cancers, 15.","DOI":"10.3390\/cancers15164026"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/cas.12408","article-title":"Disease-specific mutations in mature lymphoid neoplasms: Recent advances","volume":"105","author":"Enami","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3109\/10428194.2012.742525","article-title":"BRAF mutations in chronic lymphocytic leukemia","volume":"54","author":"Jebaraj","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3324\/haematol.2018.196931","article-title":"Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia","volume":"104","author":"Montraveta","year":"2019","journal-title":"Haematologica"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bjh.13291","article-title":"BRAF(V600E) mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients","volume":"170","author":"Sellar","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_56","first-page":"E457","article-title":"Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia","volume":"96","author":"Giza","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.60.2094","article-title":"Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma","volume":"33","author":"Lam","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bjh.18090","article-title":"Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study","volume":"197","author":"Jobson","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2011.34.9605","article-title":"Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study","volume":"30","author":"Brewer","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/CJI.0000000000000345","article-title":"Checkpoint Blockade in Melanoma Patients with Underlying Chronic Lymphocytic Leukemia","volume":"44","author":"Smithy","year":"2021","journal-title":"J. Immunother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2023.03.009","article-title":"Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies","volume":"186","author":"Eertwegh","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.leukres.2018.07.003","article-title":"Management of melanoma in patients with chronic lymphocytic leukemia","volume":"71","author":"Archibald","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Chu, Y., Liu, Y., Fang, X., Jiang, Y., Ding, M., Ge, X., Yuan, D., Lu, K., Li, P., and Li, Y. (2023). The epidemiological patterns of non-Hodgkin lymphoma: Global estimates of disease burden, risk factors, and temporal trends. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1059914"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Xie, S., Yu, Z., Feng, A., Zheng, S., Li, Y., Zeng, Y., and Lyu, J. (2022). Analysis and prediction of relative survival trends in patients with non-Hodgkin lymphoma in the United States using a model-based period analysis method. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.942122"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/jnci\/85.23.1932","article-title":"Second cancers among long-term survivors of non-Hodgkin\u2019s lymphoma","volume":"85","author":"Travis","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/bmj.310.6993.1491","article-title":"Evidence of an association between non-Hodgkin\u2019s lymphoma and skin cancer","volume":"310","author":"Adami","year":"1995","journal-title":"BMJ"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/bjh.14530","article-title":"Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: A pooled analysis of German cancer registry data (1990\u20132012)","volume":"177","author":"Baras","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/bjh.12684","article-title":"Age-time risk patterns of solid cancers in 60 901 non-Hodgkin lymphoma survivors from Finland, Norway and Sweden","volume":"164","author":"Pukkala","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1054\/bjoc.1999.1102","article-title":"Second primary neoplasms following non-Hodgkin\u2019s lymphoma in New South Wales, Australia","volume":"82","author":"Brennan","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/ijc.31801","article-title":"Second primary cancers in non-Hodgkin lymphoma: Bidirectional analyses suggesting role for immune dysfunction","volume":"143","author":"Chattopadhyay","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1054\/bjoc.2001.1998","article-title":"Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958\u20131996: A search for common mechanisms","volume":"85","author":"Dong","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ijc.2910620505","article-title":"Non-Hodgkin\u2019s lymphoma and skin malignancies-shared etiology?","volume":"62","author":"Hall","year":"1995","journal-title":"Int. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/cam4.5139","article-title":"Secondary malignancies in non-Hodgkin lymphoma survivors: 40\u2009years of follow-up assessed by treatment modality","volume":"12","author":"Parsons","year":"2023","journal-title":"Cancer Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ijc.25706","article-title":"Risk of second cancer after lymphohematopoietic neoplasm","volume":"129","author":"Royle","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clml.2017.06.028","article-title":"Risk of Second Primary Malignancies in Patients with Follicular Lymphoma: A United States Population-based Study","volume":"17","author":"Giri","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1586\/edm.10.48","article-title":"Skin cancer in patients with non-Hodgkin\u2019s lymphoma","volume":"5","author":"Brewer","year":"2010","journal-title":"Expert Rev. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10552-021-01404-6","article-title":"Sunlight exposure in association with risk of lymphoid malignancy: A meta-analysis of observational studies","volume":"32","author":"Kim","year":"2021","journal-title":"Cancer Causes Control CCC"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/bmt.2014.13","article-title":"Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: A population-based cohort study","volume":"49","author":"Ashton","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2008-05-158782","article-title":"Solid cancers after allogeneic hematopoietic cell transplantation","volume":"113","author":"Rizzo","year":"2009","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000350681","article-title":"Melanoma and Rituximab: An Incidental Association?","volume":"226","author":"Peuvrel","year":"2013","journal-title":"Dermatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"AB174","DOI":"10.1016\/j.jaad.2015.02.712","article-title":"Progression of melanoma after treatment with rituximab for lymphoma\u2014Cause or coincidence?","volume":"72","author":"Bajaj","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/CMR.0000000000000074","article-title":"Four cases of rituximab-associated melanoma","volume":"24","author":"Velter","year":"2014","journal-title":"Melanoma Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e13471","DOI":"10.1111\/dth.13471","article-title":"Is rituximab therapy a risk factor for development of melanoma?","volume":"33","author":"Cengiz","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdv616","article-title":"Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: A systematic review and meta-analysis","volume":"27","author":"Fleury","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: A global data analysis","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/ajh.25856","article-title":"Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management","volume":"95","author":"Ansell","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(12)60035-X","article-title":"Hodgkin\u2019s lymphoma in adults","volume":"380","author":"Townsend","year":"2012","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","article-title":"Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin\u2019s Disease: A Population-Based Evaluation over 25 Years","volume":"20","author":"Dores","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.clml.2018.05.021","article-title":"Trends in the Risks of Secondary Cancers in Patients with Hodgkin Lymphoma","volume":"18","author":"Kumar","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/annonc\/mdf289","article-title":"Long-term risk of second malignancy after treatment of Hodgkin\u2019s disease: The influence of treatment, age and follow-up time","volume":"13","author":"Abrahamsen","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.radonc.2013.06.041","article-title":"Long-term risk of secondary skin cancers after radiation therapy for Hodgkin\u2019s lymphoma","volume":"109","author":"Krol","year":"2013","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1182\/blood.V84.4.1209.1209","article-title":"Second Primary Cancers in Patients Continuously Disease-Free from Hodgkin\u2019s Disease: A Protective Role for the Spleen?","volume":"84","author":"Dietrich","year":"1994","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/3.suppl_4.S117","article-title":"Second cancer after the treatment for Hodgkin\u2019s disease: A report from the International Database on Hodgkin\u2019s Disease","volume":"3","year":"1992","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s002770050556","article-title":"Second malignancies after Hodgkin\u2019s disease: The Munich experience","volume":"78","author":"Munker","year":"1999","journal-title":"Ann. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2016.70.9709","article-title":"Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History","volume":"35","author":"Sud","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","article-title":"Risk of Second Malignancy After Hodgkin\u2019s Disease in a Collaborative British Cohort: The Relation to Age at Treatment","volume":"18","author":"Swerdlow","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/10428194.2021.2020775","article-title":"Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors","volume":"63","author":"Brunson","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","article-title":"Second Cancer Risk After Chemotherapy for Hodgkin\u2019s Lymphoma: A Collaborative British Cohort Study","volume":"29","author":"Swerdlow","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Nassi, L., De Sanctis, V., Loseto, G., Gerardi, C., Allocati, E., Ciavarella, S., Minoia, C., Guarini, A., and Bari, A. (2022). Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi. Cancers, 14.","DOI":"10.3390\/cancers14030519"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Rosenbrock, J., Kaul, H., Oertel, M., Celik, E., Linde, P., Fan, J., Eichenauer, D.A., Br\u00f6ckelmann, P.J., von Tresckow, B., and Kobe, C. (Int. J. Radiat. Oncol. Biol. Phys., 2024). Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma\u2014An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group, Int. J. Radiat. Oncol. Biol. Phys., Online ahead of print.","DOI":"10.1016\/j.ijrobp.2024.04.015"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3857\/roj.2015.33.3.161","article-title":"Image-guided radiation therapy in lymphoma management","volume":"33","author":"Eng","year":"2015","journal-title":"Radiat. Oncol. J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/acm2.12575","article-title":"A new frontier of image guidance: Organs at risk avoidance with MRI-guided respiratory-gated intensity modulated radiotherapy: Technical note and report of a case","volume":"20","author":"Massaccesi","year":"2019","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_105","first-page":"368","article-title":"Primary cutaneous lymphomas: Diagnosis and treatment","volume":"32","year":"2015","journal-title":"Adv. Dermatol. Allergol. Dermatol. Alergol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Miyashiro, D., and Sanches, J.A. (2023). Mycosis fungoides and S\u00e9zary syndrome: Clinical presentation, diagnosis, staging, and therapeutic management. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1141108"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaad.2019.07.075","article-title":"Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis","volume":"83","author":"Goyal","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archderm.143.1.45","article-title":"Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: Evidence from population-based and clinical cohorts","volume":"143","author":"Huang","year":"2007","journal-title":"Arch. Dermatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3816\/CLM.2008.n.011","article-title":"Increased malignancy risk in the cutaneous T-cell lymphoma patient population","volume":"8","author":"Brownell","year":"2008","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jaad.2019.11.051","article-title":"Gender differences in the risk of secondary malignancies in patients with mycosis fungoides and S\u00e9zary syndrome","volume":"83","author":"Almukhtar","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaad.2014.03.044","article-title":"Subsequent cancers, mortality, and causes of death in patients with mycosis fungoides and parapsoriasis: A Danish nationwide, population-based cohort study","volume":"71","author":"Lindahl","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.2340\/00015555-3704","article-title":"Melanoma Risk is Increased in Patients with Mycosis Fungoides Compared with Patients with Psoriasis and the General Population","volume":"100","author":"Sherman","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/archderm.1995.01690160060009","article-title":"Malignant melanoma and other second cutaneous malignancies in cutaneous T-cell lymphoma. The influence of additional therapy after total skin electron beam radiation","volume":"131","author":"Licata","year":"1995","journal-title":"Arch. Dermatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.clon.2018.06.006","article-title":"Total Skin Electron Irradiation and Sequential Malignancies in Mycosis Fungoides Patients: Longitudinal Study","volume":"30","author":"Lutsyk","year":"2018","journal-title":"Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjd.12620","article-title":"Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: A 30-year population-based cohort study","volume":"170","author":"Lindahl","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jaad.2003.11.054","article-title":"Cutaneous malignant melanoma in association with mycosis fungoides","volume":"50","author":"Evans","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"289","DOI":"10.5114\/ada.2021.106205","article-title":"The incidences of other primary cancers in patients with mycosis fungoides and S\u00e9zary syndrome","volume":"38","author":"Olszewska","year":"2021","journal-title":"Adv. Dermatol. Allergol. Dermatol. Alergol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/pde.13738","article-title":"Multiple melanocytic nevi restricted to mycosis fungoides patches in pediatric and young-adult patients. The potential role of local immunosuppression","volume":"36","author":"Amin","year":"2019","journal-title":"Pediatr. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.0022-202x.2001.01682.x","article-title":"Frequent Abnormalities of the P15 and P16 Genes in Mycosis Fungoides and Sezary Syndrome","volume":"118","author":"Scarisbrick","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Gniadecki, R., O\u2019Keefe, S., Hennessey, D., and Iyer, A. (2023). Is Cutaneous T-Cell Lymphoma Caused by Ultraviolet Radiation? A Comparison of UV Mutational Signatures in Malignant Melanoma and Mycosis Fungoides. Cells, 12.","DOI":"10.20944\/preprints202305.1290.v1"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Padala, S.A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., and Ajebo, G.H. (2021). Epidemiology, Staging, and Management of Multiple Myeloma. Med. Sci., 9.","DOI":"10.3390\/medsci9010003"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"101144","DOI":"10.1016\/j.beha.2020.101144","article-title":"Second malignancies in multiple myeloma; emerging patterns and future directions","volume":"33","author":"Maclachlan","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/ejh.12748","article-title":"Risk of skin cancer in multiple myeloma patients: A retrospective cohort study","volume":"97","author":"Robinson","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"AB175","DOI":"10.1016\/j.jaad.2015.02.718","article-title":"Risk of malignant melanoma in patients with multiple myeloma","volume":"72","author":"Chang","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/ejh.13581","article-title":"Patterns of previous and secondary malignancies in patients with multiple myeloma","volume":"106","author":"Langseth","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1038\/bcj.2013.19","article-title":"Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics","volume":"3","author":"Razavi","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.bbmt.2014.12.028","article-title":"New Cancers after Autotransplants for Multiple Myeloma","volume":"21","author":"Mahindra","year":"2015","journal-title":"Biol. Blood Marrow Transpl. J. Am. Soc. Blood Marrow Transpl."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbmt.2006.11.003","article-title":"Philadelphia Chromosome\u2013Negative Myeloproliferative Disorders: Biology and Treatment","volume":"13","author":"Hoffman","year":"2007","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: A Danish population-based cohort study","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41375-018-0027-y","article-title":"Second malignancies in patients with myeloproliferative neoplasms: A population-based cohort study of 9379 patients","volume":"32","author":"Landtblom","year":"2018","journal-title":"Leukemia"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S2352-3026(18)30108-X","article-title":"Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: A nationwide, observational follow up study in Sweden","volume":"5","author":"Chattopadhyay","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2141.2010.08538.x","article-title":"Higher risk of primary cancers after polycythaemia vera and vice versa","volume":"153","author":"Fallah","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1080\/10428194.2022.2123227","article-title":"Risk of second primary malignancy in patients with primary myelofibrosis: A SEER database study","volume":"63","author":"Joshi","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood-2011-12-401455","article-title":"Risk of second cancers in chronic myeloproliferative neoplasms","volume":"119","author":"Susini","year":"2012","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1056\/NEJM199703273361301","article-title":"Solid Cancers after Bone Marrow Transplantation","volume":"336","author":"Curtis","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41409-018-0290-6","article-title":"Incidence and risk factors of secondary cancers after allogeneic stem cell transplantation: Analysis of a single centre cohort with a long follow-up","volume":"54","author":"Martelin","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamaoncol.2018.4934","article-title":"Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients","volume":"5","author":"Tichelli","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jamadermatol.2015.3902","article-title":"Skin Cancer Risk in Hematopoietic Stem-Cell Transplant Recipients Compared with Background Population and Renal Transplant Recipients: A Population-Based Cohort Study","volume":"152","author":"Omland","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Killeen, T.F., Shanley, R., Ramesh, V., and Giubellino, A. (2023). Malignant Melanoma in a Retrospective Cohort of Immunocompromised Patients: A Statistical and Pathologic Analysis. Cancers, 15.","DOI":"10.3390\/cancers15143600"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1002\/cncr.32941","article-title":"Morbidity Burden in Multiple Myeloma Survivors of Autologous Transplant\u2014A Bone Marrow Transplant Survivor Study (BMTSS)","volume":"126","author":"Arora","year":"2020","journal-title":"Cancer"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jaad.2019.10.034","article-title":"Risk factors for the development of cutaneous melanoma after allogeneic hematopoietic cell transplantation","volume":"83","author":"Herr","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mpo.1128","article-title":"Radiation-induced skin cancer in human","volume":"36","author":"Shore","year":"2001","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2217\/mmt-2016-0022","article-title":"Skin cancer screening: Recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy","volume":"4","author":"Johnson","year":"2017","journal-title":"Melanoma Manag."},{"key":"ref_144","first-page":"e101","article-title":"Risk of Melanoma among Survivors of Hematologic Malignancies","volume":"1","author":"Hepner","year":"2016","journal-title":"Adv. Cancer Prev."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"11531","DOI":"10.1007\/s00432-023-04984-9","article-title":"Preventive health care in blood cancer survivors: Results from the ABC study","volume":"149","author":"Baum","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/15\/4501\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:28:08Z","timestamp":1760110088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/15\/4501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":145,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jcm13154501"],"URL":"https:\/\/doi.org\/10.3390\/jcm13154501","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}